2026 Q1 Portfolio Activity
In 2026 Q1, Commodore Capital LP maintained a portfolio of 46 distinct positions. The most significant new addition was ERASCA INC, now representing 2.97% of the total fund value. They heavily accumulated shares in ALKERMES PLC, increasing the position by 18.3%. Conversely, Commodore Capital LP completely exited their position in TERNS PHARMACEUTICALS INC.
Position History
hover any row below to update
Loading…
Total Positions
46
Quarter
2026 Q1
Top Holding
RLAY (9.8%)
Top 10 Concentration
61.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-46 of 46
Commodore Capital LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 9.79% | 9.57% |
#1
Prev: #1
|
6.9 |
—
|
no change | no change |
P
S
|
17,000,000 | $169,150,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 8.59% | 6.61% |
#2
Prev: #2
|
6.9 |
—
|
650,000 | 18.3% |
P
S
|
4,200,000 | $148,512,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 7.43% | 4.81% |
#3
4
Prev: #7
|
4.0 |
—
|
-1,417,809 | -30.2% |
P
S
|
3,275,000 | $128,380,000 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 6.43% | 5.19% |
#4
2
Prev: #6
|
5.6 |
—
|
691,162 | 31.5% |
P
S
|
2,888,007 | $111,159,389 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 5.58% | 5.21% |
#5
Prev: #5
|
3.2 |
—
|
-475,865 | -19.9% |
P
S
|
1,912,380 | $96,460,447 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 5.48% | 5.91% |
#6
3
Prev: #3
|
2.2 |
—
|
-900,000 | -26.7% |
P
S
|
2,475,000 | $94,792,500 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 4.95% | 4.64% |
#7
1
Prev: #8
|
4.0 |
—
|
131,616 | 5.1% |
P
S
|
2,696,616 | $85,536,660 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NUVL
NUVALENT INC
|
Healthcare | 4.94% | 3.68% |
#8
5
Prev: #13
|
5.0 |
—
|
283,600 | 51.6% |
P
S
|
833,600 | $85,402,320 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 4.54% | 4.54% |
#9
Prev: #9
|
2.8 |
—
|
no change | no change |
P
S
|
5,650,000 | $78,535,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 3.61% | 3.88% |
#10
1
Prev: #11
|
2.4 |
—
|
no change | no change |
P
S
|
750,000 | $62,467,500 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 3.54% | 2.16% |
#11
10
Prev: #21
|
3.9 |
—
|
900,000 | 49.4% |
P
S
|
2,723,196 | $61,217,446 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 3.14% | 3.49% |
#12
3
Prev: #15
|
1.8 |
—
|
29,525 | 1.6% |
P
S
|
1,918,970 | $54,210,903 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ERAS
ERASCA INC
|
Healthcare | 2.97% | — |
#13
Prev: #—
|
4.7 |
—
|
3,175,000 | — |
NEW
|
3,175,000 | $51,371,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GLTO
DAMORA THERAPEU...
|
Healthcare | 2.91% | — |
#14
Prev: #—
|
4.7 |
—
|
1,939,000 | — |
NEW
|
1,939,000 | $50,220,100 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.78% | 5.37% |
#15
11
Prev: #4
|
1.1 |
—
|
-975,000 | -54.2% |
P
S
|
825,000 | $47,973,750 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 2.19% | — |
#16
Prev: #—
|
4.4 |
—
|
2,000,000 | — |
NEW
|
2,000,000 | $37,800,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 2.14% | 2.22% |
#17
2
Prev: #19
|
1.9 |
—
|
no change | no change |
P
S
|
1,500,000 | $36,990,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 2.11% | — |
#18
Prev: #—
|
4.3 |
—
|
2,825,000 | — |
NEW
|
2,825,000 | $36,414,250 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.04% | 2.87% |
#19
3
Prev: #16
|
1.8 |
—
|
no change | no change |
P
S
|
2,275,000 | $35,262,500 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 1.91% | — |
#20
Prev: #—
|
4.3 |
—
|
2,258,735 | — |
NEW
|
2,258,735 | $33,045,293 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 1.61% | 2.26% |
#21
3
Prev: #18
|
1.6 |
—
|
no change | no change |
P
S
|
1,000,000 | $27,750,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 1.53% | — |
#22
Prev: #—
|
4.1 |
—
|
6,336,782 | — |
NEW
|
6,336,782 | $26,424,381 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 1.26% | 3.70% |
#23
11
Prev: #12
|
0.5 |
—
|
-547,568 | -45.6% |
P
S
|
652,432 | $21,843,423 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 1.26% | — |
#24
Prev: #—
|
4.0 |
—
|
2,575,000 | — |
NEW
|
2,575,000 | $21,810,250 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.14% | — |
#25
Prev: #—
|
4.0 |
—
|
8,695,652 | — |
NEW
|
8,695,652 | $19,652,174 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 1.12% | — |
#26
Prev: #—
|
3.9 |
—
|
3,250,000 | — |
NEW
|
3,250,000 | $19,337,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 0.98% | 1.10% |
#27
1
Prev: #26
|
1.4 |
—
|
no change | no change |
P
S
|
4,401,500 | $16,857,745 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 0.73% | 1.79% |
#28
6
Prev: #22
|
0.3 |
—
|
-4,263,938 | -37.3% |
P
S
|
7,181,062 | $12,566,859 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KPTI
KARYOPHARM THER...
|
Healthcare | 0.63% | — |
#29
Prev: #—
|
3.8 |
—
|
1,950,000 | — |
NEW
|
1,950,000 | $10,861,500 | 2022 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 0.52% | 0.74% |
#30
2
Prev: #28
|
1.2 |
—
|
no change | no change |
P
S
|
5,397,488 | $9,067,780 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ANTX
AN2 THERAPEUTIC...
|
Healthcare | 0.46% | — |
#31
Prev: #—
|
3.7 |
—
|
2,333,713 | — |
NEW
|
2,333,713 | $7,981,298 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PEPG
PEPGEN INC
|
Healthcare | 0.46% | 1.47% |
#32
7
Prev: #25
|
2.7 |
—
|
1,075,000 | 31.6% |
P
S
|
4,475,000 | $7,920,750 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.42% | 0.58% |
#33
3
Prev: #30
|
1.2 |
—
|
no change | no change |
P
S
|
483,000 | $7,211,190 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 0.29% | — |
#34
Prev: #—
|
3.6 |
—
|
500,000 | — |
NEW
|
500,000 | $5,080,000 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
LONA
LEONABIO INC
|
Healthcare | 0.28% | 0.23% |
#35
3
Prev: #32
|
1.1 |
—
|
no change | no change |
P
S
|
464,398 | $4,774,011 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 0.26% | — |
#36
Prev: #—
|
3.6 |
—
|
633,901 | — |
NEW
|
633,901 | $4,411,951 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 0.00% | 0.10% |
Sold All 😨
(Was: #33) |
0.0 |
—
|
-18,851 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 0.00% | 0.56% |
Sold All 😨
(Was: #31) |
0.0 |
—
|
-250,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 0.00% | 0.62% |
Sold All 😨
(Was: #29) |
0.0 |
—
|
-816,326 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 0.00% | 0.92% |
Sold All 😨
(Was: #27) |
0.0 |
—
|
-1,425,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.00% | 1.66% |
Sold All 😨
(Was: #24) |
0.0 |
—
|
-1,000,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
MNMD
MIND MEDICINE M...
|
Unknown | 0.00% | 1.78% |
Sold All 😨
(Was: #23) |
0.0 |
—
|
-2,000,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 0.00% | 2.18% |
Sold All 😨
(Was: #20) |
0.0 |
—
|
-7,692,300 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.00% | 2.62% |
Sold All 😨
(Was: #17) |
0.0 |
—
|
-450,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 0.00% | 3.54% |
Sold All 😨
(Was: #14) |
0.0 |
—
|
-1,753,054 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 0.00% | 3.97% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-1,475,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-46 of 46 holdings